Salih ÖZÇOBANOĞLU, Filiz EKİCİ, Fırat KARDELEN

Premature Coronary Artery Disease due to Homozygous Familial Hypercholesterolemia in a 12-Year-Old Girl

Background: Homozygous familial hypercholesterolemia is a rare inherited metabolic disease caused by low-density lipoprotein receptor abnormality. Patients with homozygous familial hypercholesterolemia have an increased risk of cardiovascular complication that usually occurs in the first decade of life. Here, we report a 12-year-old girl with an unpredicted presentation for coronary artery disease and found to have homozygous familial hypercholesterolemia. Case Report: A 12-year-old girl was admitted to our unit with syncope. Chest X-ray showed bilateral diffuse pneumonic consolidation and mild cardiomegaly. We detected stable ST depression by electrocardiography. Echocardiography showed normal systolic functions. Troponin-1 levels were high (66 mcg/dL, upper limit: 0.04 mcg/dL). Influenza A virus DNA was detected by the respiratory viral panel. After her successful treatment for acute pneumonia and myocarditis due to Influenza A virus, her syncope attacks persisted. Marked ST elevation was observed during exercise electrocardiography. Coronary angiography showed severe occlusions in the coronary arteries. High serum levels of total cholesterol (756 mg/dL) and low-density lipoprotein-C (556 mg/dL) were noticed. She had no tendon xanthomas. Medical histories revealed that her family members were diagnosed with heterozygous familial hypercholesterolemia. A coronary bypass surgery was performed. Statin and ezetimibe treatments were started. We also planned lipid apheresis. Conclusion: Children with homozygous familial hypercholesterolemia may present with symptoms of premature coronary heart disease requiring a routine lipid test and careful anamnesis.

PDF

___

1. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015;36:2425-37.
2. Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015;36:560-5.
3. Widhalm K, Binder CB, Kreissl A, Aldover-Macasaet E, Fritsch M, Kroisboeck S, et al. Sudden death in a 4-year-old boy: a near-complete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. J Pediatr 2011;158:167.
4. Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008;102:1438-43.
5. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007;27:1803-10.
6. Alim A, Tokat Y, Erdogan Y, Gokkaya Z, Dayangac M, Yuzer Y, et al. Liver transplantation for homozygote familial hypercholesterolemia: the only curative treatment. Pediatr Transplant 2016;20:1060-4.
7. Kayıkçıoğlu M, Kısmalı E, Can L, Payzin S. [Long-term follow-up in patients with homozygous familial hypercholesterolemia; 13-year experience of a university hospital lipid clinic]. Turk Kardiyol Dern Ars 2014;42:599-611.
8. Lin M, Dai H, Zhao S. Long-term atorvastatin-ezetimibe-probucol triple therapy for homozygous familial hypercholesterolaemia from early childhood. Cardiol Young 2016;26:197-201.
9. Schneider AE, Johnson JN, Taggart NW, Cabalka AK, Hagler DJ, Reeder GS, et al. Percutaneous coronary intervention in pediatric and adolescent patients. Congenit Heart Dis 2014;9:228-34.
10. Bilal MS, Aydemir NA, Cine N, Celebi A, Kaplan M. Triple coronary bypass in a child with homozygous familial hypercholesterolemia. Heart Surg Forum 2005;8:351-3.
11. Nemati MH. Coronary revascularization in a child with homozygous familial hypercholesterolemia. Interact Cardiovasc Thorac Surg 2010;10:131-2.
12. Oral MK, Polat B, Ezelsoy M. Ten-year follow-up of coronary revascularization in a pediatric case with homozygous familial hypercholesterolemia. Cardiovasc Surg Int 2016;3:73-6.
13. Nazif TM, Kalra S, Ali ZA, Karmpaliotis D, Turner ME, Starc TJ, et al. Percutaneous Coronary Intervention With Bioresorbable Scaffolds in a Young Child. JAMA Cardiol 2017;2:430-4.